{"paper_id": "1c914d9d3e8011efd09ffdfa00850b70328effcf", "metadata": {"title": "Journal Pre-proof In vitro and Animal Models for SARS-CoV-2 research In vitro and Animal Models for SARS-CoV-2 research Author/Affiliation", "authors": [{"first": "Kazuo", "middle": [], "last": "Takayama", "suffix": "", "affiliation": {"laboratory": "", "institution": "Kyoto University", "location": {"postCode": "606-8507", "settlement": "Kyoto", "country": "Japan"}}, "email": "kazuo.takayama@cira.kyoto-u.ac.jp"}, {"first": "", "middle": [], "last": "Kazuo Takayama", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Basic research on SARS-CoV-2 is essential to understand its detailed pathophysiology and identify best drug targets. Models that can faithfully reproduce the viral life cycle and reproduce the pathology of COVID-19 are required. Here, we briefly review the cell lines, organoids, and animal models that are currently being used in COVID-19 research. Journal Pre-proof J o u r n a l P r e -p r o o f", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "In December 2019, pneumonia of an unknown etiology was confirmed in China [1] . The Chinese Center for Disease Control and Prevention (CCDC) identified a novel coronavirus infection as the cause of this pneumonia [2] . The World Health Organization (WHO) named the disease \"2019-new coronavirus disease\" (or i and the International Committee on Taxonomy of Viruses (ICTV) named the virus \"severe acute respiratory syndrome coronavirus 2\" (or SARS-CoV-2) ii . The WHO soon declared that COVID-19 was a fast-evolving pandemic iii . As of May, 26, 2020 , it is estimated that 5,406,282 people have been infected with COVID-19 and 343,562 people have died globally iii . Multiple clinical trials are currently underway for prevention or intervention in the disease progression [3] . In parallel, it is also equally essential to carry out basic research on SARS-CoV-2 to support the efficient development of therapeutic agents. For this, models that can faithfully reproduce the behavior of the virus and reproduce the pathology of COVID-19 are required. Here, we briefly review relevant cell lines, organoids, and animal model animals.", "cite_spans": [{"start": 74, "end": 77, "text": "[1]", "ref_id": "BIBREF0"}, {"start": 213, "end": 216, "text": "[2]", "ref_id": "BIBREF1"}, {"start": 541, "end": 544, "text": "26,", "ref_id": "BIBREF25"}, {"start": 545, "end": 549, "text": "2020", "ref_id": null}, {"start": 773, "end": 776, "text": "[3]", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "Overview of SARS-CoV-2"}, {"text": "An in vitro cell model for SARS-CoV-2 research is essential for understanding the viral life cycle, for amplifying and isolating the virus for further research and for preclinical evaluation of therapeutic molecules. This section lays out the cell lines used to replicate and isolate SARS-CoV-2, as well as organoids that can be used to examine the effects of SARS-CoV-2 infection on specific human tissues (Table 1A, Figure 1 ).", "cite_spans": [], "ref_spans": [{"start": 418, "end": 426, "text": "Figure 1", "ref_id": "FIGREF3"}], "section": "Cell lines and organoids for SARS-CoV-2 research"}, {"text": "In humans, airway epithelial cells highly express the putative SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine [12] . They reported that the viral RNA copies in the culture supernatants of these cells were >100 times higher than those of Vero E6 cells, suggesting that it would possible to isolate higher titer virus using TMPRSS2-overexpressing Vero E6 cells.", "cite_spans": [{"start": 154, "end": 158, "text": "[12]", "ref_id": "BIBREF11"}], "ref_spans": [], "section": "Cell lines"}, {"text": "Organoids are composed of multiple cell types and model the physiological conditions of human organs. Because organoids have the ability to self-replicate, they are also suitable models for large-scale screening in drug discovery and disease research [13] . Besides the lung damage caused by pneumonia, SARS-CoV-2 affects several organs like the kidney [14] , liver [15] , and the cardiovascular system [16] . Suzuki et al.", "cite_spans": [{"start": 251, "end": 255, "text": "[13]", "ref_id": "BIBREF12"}, {"start": 353, "end": 357, "text": "[14]", "ref_id": "BIBREF13"}, {"start": 366, "end": 370, "text": "[15]", "ref_id": "BIBREF14"}, {"start": 403, "end": 407, "text": "[16]", "ref_id": "BIBREF15"}], "ref_spans": [], "section": "Organoids"}, {"text": "and Han et al. generated human bronchial organoids [17] or human lung organoids [18] , respectively, for SARS-CoV-2 research. They showed that their organoids were permissive to the SARS-CoV-2 infection and could evaluate anti-viral effects of COVID-19 candidate therapeutic compounds including camostat [17] . Besides the lung damage caused by pneumonia, SARS-CoV-2 affects several organs like the kidney [14] , liver [15] , and the cardiovascular system [16] . Monteil infection and support replication [20] . Interestingly, virus infection impaired the bile acid transporting functions of cholangiocytes [20] . This effect might be the reason for Furthermore, it is expected that the intestine is another viral target organ [21] . Lamers ", "cite_spans": [{"start": 51, "end": 55, "text": "[17]", "ref_id": "BIBREF16"}, {"start": 80, "end": 84, "text": "[18]", "ref_id": "BIBREF17"}, {"start": 304, "end": 308, "text": "[17]", "ref_id": "BIBREF16"}, {"start": 406, "end": 410, "text": "[14]", "ref_id": "BIBREF13"}, {"start": 419, "end": 423, "text": "[15]", "ref_id": "BIBREF14"}, {"start": 456, "end": 460, "text": "[16]", "ref_id": "BIBREF15"}, {"start": 463, "end": 470, "text": "Monteil", "ref_id": null}, {"start": 505, "end": 509, "text": "[20]", "ref_id": "BIBREF19"}, {"start": 607, "end": 611, "text": "[20]", "ref_id": "BIBREF19"}, {"start": 727, "end": 731, "text": "[21]", "ref_id": "BIBREF20"}, {"start": 734, "end": 740, "text": "Lamers", "ref_id": null}], "ref_spans": [], "section": "Organoids"}, {"text": "The complex pathophysiology of the disease will only be understood by Figure 1 ).", "cite_spans": [], "ref_spans": [{"start": 70, "end": 78, "text": "Figure 1", "ref_id": "FIGREF3"}], "section": "Animal models for SARS-CoV-2 research"}, {"text": "One of the works that set the pace for discovery of animal models was by Zhou et al. who conducted SARS-CoV-2 infection experiments using HeLa cells that expressed ACE2 proteins taken from multiple animal species from mice to humans [11] .", "cite_spans": [{"start": 233, "end": 237, "text": "[11]", "ref_id": "BIBREF10"}], "ref_spans": [], "section": "Small animals"}, {"text": "Interestingly, SARS-CoV-2 could use all ACE2 proteins, except for mouse ACE2.", "cite_spans": [], "ref_spans": [], "section": "Small animals"}, {"text": "Therefore, Bao et al. used transgenic mice that express human ACE2 [25] . The team found that such mice after SARS-CoV-2 infection, showed weight loss, virus replication in the lungs, and interstitial pneumonia [25] . In the search of alternative small animal models, molecular docking studies were performed on the binding between ACE2 of various mammals and the S protein of SARS-CoV-2, with the finding that the Syrian hamster might be suitable [26] . After infection, these hamsters show rapid breathing, weight loss, and alveolar damage with extensive apoptosis [26] .", "cite_spans": [{"start": 67, "end": 71, "text": "[25]", "ref_id": "BIBREF24"}, {"start": 211, "end": 215, "text": "[25]", "ref_id": "BIBREF24"}, {"start": 448, "end": 452, "text": "[26]", "ref_id": "BIBREF25"}, {"start": 567, "end": 571, "text": "[26]", "ref_id": "BIBREF25"}], "ref_spans": [], "section": "Small animals"}, {"text": "J o u r n a l P r e -p r o o f Figure 1 ) and help assess the advantages and disadvantages of each towards discovery of better models.", "cite_spans": [], "ref_spans": [{"start": 31, "end": 39, "text": "Figure 1", "ref_id": "FIGREF3"}], "section": "Small animals"}, {"text": "J o u r n a l P r e -p r o o f manuscript. We also thank Dr. Eiri Ono (Kyoto University) for creating the figure.", "cite_spans": [], "ref_spans": [], "section": "Small animals"}, {"text": "The author has no conflict of interests. Human ACE2 transgenic mice After SARS-CoV-2 infection, the mice show weight loss, virus replication in the lungs, and interstitial pneumonia.", "cite_spans": [], "ref_spans": [], "section": "Disclaimer Statement"}, {"text": "[25]", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "Syrian hamster After SARS-CoV-2 infection, the hamsters show rapid breathing, weight loss, and diffuse alveolar damage with extensive apoptosis.", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "[26]", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "Ferrets After SARS-CoV-2 infection, acute bronchiolitis was observed in the lungs.", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "[27]", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "Cats After SARS-CoV-2 infection, intra-alveolar edema and congestion in the interalveolar septa were observed.", "cite_spans": [], "ref_spans": [], "section": "Resources"}, {"text": "Abnormal arrangement of the epithelium with loss of cilia and lymphocytic infiltration into the lamina propria were also observed. ", "cite_spans": [], "ref_spans": [], "section": "Resources"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle", "authors": [{"first": "H", "middle": [], "last": "Lu", "suffix": ""}], "year": null, "venue": "Journal of Medical Virology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia", "authors": [{"first": "Q", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "New England Journal of Medicine", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Ongoing Clinical Trials for the Management of the COVID-19 Pandemic", "authors": [{"first": "M", "middle": ["P"], "last": "Lythgoe", "suffix": ""}, {"first": "P", "middle": [], "last": "Middleton", "suffix": ""}], "year": 2020, "venue": "Trends Pharmacol Sci", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", "authors": [{"first": "M", "middle": [], "last": "Hoffmann", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "A novel coronavirus from patients with pneumonia in China", "authors": [{"first": "N", "middle": [], "last": "Zhu", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Identification of Coronavirus Isolated from a Patient in Korea with COVID-19", "authors": [{"first": "J.-M", "middle": [], "last": "Kim", "suffix": ""}], "year": 2020, "venue": "Osong Public Health and Research Perspectives", "volume": "11", "issn": "1", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV", "authors": [{"first": "X", "middle": [], "last": "Ou", "suffix": ""}], "year": 2020, "venue": "Nature communications", "volume": "11", "issn": "1", "pages": "1--12", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient", "authors": [{"first": "J", "middle": [], "last": "Harcourt", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)", "authors": [{"first": "J", "middle": [], "last": "Desmyter", "suffix": ""}], "year": 1968, "venue": "Journal of virology", "volume": "2", "issn": "10", "pages": "955--961", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "The genome landscape of the african green monkey kidney-derived vero cell line", "authors": [{"first": "N", "middle": [], "last": "Osada", "suffix": ""}], "year": 2014, "venue": "DNA research", "volume": "21", "issn": "6", "pages": "673--683", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "authors": [{"first": "P", "middle": [], "last": "Zhou", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "579", "issn": "7798", "pages": "270--273", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells", "authors": [{"first": "S", "middle": [], "last": "Matsuyama", "suffix": ""}], "year": 2020, "venue": "Proceedings of the National Academy of Sciences", "volume": "117", "issn": "13", "pages": "7001--7003", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Drug discovery through stem cell-based organoid models", "authors": [{"first": "A", "middle": [], "last": "Ranga", "suffix": ""}], "year": 2014, "venue": "Advanced drug delivery reviews", "volume": "69", "issn": "", "pages": "19--28", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv", "authors": [{"first": "Z", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Clinical Features of COVID-19-Related Liver Damage", "authors": [{"first": "Z", "middle": [], "last": "Fan", "suffix": ""}], "year": 2020, "venue": "Clinical Gastroenterology and Hepatology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "COVID-19 and the cardiovascular system", "authors": [{"first": "Y.-Y", "middle": [], "last": "Zheng", "suffix": ""}], "year": 2020, "venue": "Nature Reviews Cardiology", "volume": "17", "issn": "5", "pages": "259--260", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Generation of human bronchial organoids for SARS-CoV-2 research. bioRxiv", "authors": [{"first": "T", "middle": [], "last": "Suzuki", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids. bioRxiv", "authors": [{"first": "Y", "middle": [], "last": "Han", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2", "authors": [{"first": "V", "middle": [], "last": "Monteil", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids", "authors": [{"first": "B", "middle": [], "last": "Zhao", "suffix": ""}], "year": 2020, "venue": "Protein & Cell", "volume": "", "issn": "", "pages": "1--5", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Effect of gastrointestinal symptoms on patients infected with COVID-19", "authors": [{"first": "Z", "middle": [], "last": "Zhou", "suffix": ""}], "year": 2020, "venue": "Gastroenterology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "SARS-CoV-2 productively infects human gut enterocytes", "authors": [{"first": "M", "middle": ["M"], "last": "Lamers", "suffix": ""}], "year": 2020, "venue": "Science", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Infection of bat and human intestinal organoids by SARS-CoV-2", "authors": [{"first": "J", "middle": [], "last": "Zhou", "suffix": ""}], "year": 2020, "venue": "Nature medicine", "volume": "", "issn": "", "pages": "1--7", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Endothelial cell infection and endotheliitis in COVID-19", "authors": [{"first": "Z", "middle": [], "last": "Varga", "suffix": ""}], "year": 2020, "venue": "The Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice", "authors": [{"first": "L", "middle": [], "last": "Bao", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for", "authors": [{"first": "J", "middle": ["F"], "last": "Chan", "suffix": ""}, {"first": ".-W", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "acid accumulation and consequent liver damage in patients with COVID-19.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "reproducing tissue-specific and systemic virus-host interactions. While cell lines and organoids are faster systems to study the virus and its interactions inside host cells, these can only reproduce the symptoms of COVID-19 in a specific cell type or organ, respectively. On the other hand, the pathology of COVID-19 can be reproduced and observed in a tissue-specific and systemic manner in animal models. Several different animals are being used to study the disease and to test candidate therapeutic compounds (", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Shi, J. et al. (2020) Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 29. Rockx, B. et al. (2020) Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 30. Chandrashekar, A. et al. (2020) SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 31. van Doremalen, N. et al. (2020) ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv, 2020.05.13.093195. 32. Yu, J. et al. (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 33. Williamson, B.N. et al. (2020) Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv, 2020.04.15.043166.", "latex": null, "type": "figure"}, "FIGREF3": {"text": "macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. The therapeutic effects of adenovirus-vectored vaccine, DNA vaccine candidates expressing S protein, and remdesivir treatment could be evaluated. Schematic showing a decision flowchart of cell lines, organoids, and animal models in studying COVID-19 pathophysiology. Figure created with Biorender (https://biorender.com).", "latex": null, "type": "figure"}, "TABREF2": {"text": "et al. and Zhou et al. have reported that human intestinal organoids, which were established from primary gut epithelial stem cells, support SARS-CoV-2 replication [22, 23]. Moreover, Monteil et al. have also demonstrated that SARS-CoV-2 can directly infect human blood vessel organoids differentiated from human induced pluripotent stem cells [19]. Consistently, Varga et al. confirmed the presence of viral elements within endothelial cells and an accumulation of inflammatory cells [24]. Taken together, the two studies suggest that SARS-CoV-2 infection induces endotheliitis in several organs as a direct consequence of virus involvement. However, while organoids can reproduce the pathology of COVID-19 in specific tissues on which they are modelled, they cannot reproduce the systemic symptoms associated with whole body responses to the viral infection.", "latex": null, "type": "table"}, "TABREF3": {"text": "", "latex": null, "type": "table"}, "TABREF4": {"text": "on type I pneumocytes led to pulmonary edema and the formation of hyaline membranes. Thus, cynomolgus macaques can be infected with SARS-CoV-2 and reproduce some of the human pathologies of COVID-19.Rhesus macaques have also been be used in where the is that the reproduction rate in cynomolgus and rhesus monkeys is less and slower.Hence this can be preceded by experiments with transgenic mice and Syrian hamsters. Remarks COVID-19 has spread rapidly all over the world in the last five months. Even now, the number of infected people and deaths continues to rise. At this time, there are no therapeutic prevention or intervention methods available. The only ways to control the pandemic and reduce associated loss of lives has been to change people behavior, like quarantine and social distancing. Therapeutic strategies for prevention and/ or intervention is the need of the hour. While multiple clinical trials are currently underway, in parallel, pre-clinical research on in vitro and model organisms is also needed, both to understand the virus and to test therapeutic agents for safety and efficacy. We believe", "latex": null, "type": "table"}, "TABREF6": {"text": "Table listingthe cell lines and organoids (A) and animal models (B)", "latex": null, "type": "table"}, "TABREF7": {"text": "Cell lines and organoids", "latex": null, "type": "table"}, "TABREF8": {"text": "Animal models", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Mice </td><td>Wild-type </td><td>SARS-CoV-2 cannot invade cells through mouse Ace2. </td><td>[11] </td></tr><tr><td>mice </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Human ACE2 transgenic </td><td>After SARS-CoV-2 infection, the mice show weight loss, virus replication in the lungs, and interstitial pneumonia. </td><td>[25] </td></tr><tr><td>\u00a0</td><td>mice </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Syrian hamster </td><td>of\nAfter SARS-CoV-2 infection, the hamsters show rapid breathing, weight loss, and diffuse alveolar damage with extensive apoptosis. </td><td>[26] </td></tr><tr><td>Ferrets </td><td>roAfter SARS-CoV-2 infection, acute bronchiolitis was observed in the lungs. </td><td>[27] </td></tr><tr><td>Cats </td><td>\u00a0</td><td>Pre-pAfter SARS-CoV-2 infection, intra-alveolar edema and congestion in the interalveolar septa were observed. Abnormal arrangement of the epithelium with loss of cilia and lymphocytic infiltration into the lamina propria were also observed. </td><td>[28] </td></tr><tr><td>Cynomolgus macaques </td><td>l SARS-CoV-2 can infect both type I and type II </td><td>[29] </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>rnapneumocytes. After SARS-CoV-2 infection, pulmonary consolidation, pneumonia, and edema fluid in alveolar lumina were observed. </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Rhesus macaques </td><td>JouInfected macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. The therapeutic effects of adenovirus-vectored vaccine, DNA vaccine candidates expressing S protein, and remdesivir treatment could be evaluated. </td><td>[30-33] </td></tr></table></body></html>"}}, "back_matter": []}